Purpose: Nonsteroidal anti-inflammatory drugs that prohibit biosynthesis of arachidonic acid metabolites have been considered potent host modulation agents. The aim of this review was to determine the effect of nonsteroidal anti-inflammatory drugs adjunctive with nonsurgical periodontal treatment in patients with periodontal disease. Materials and Methods: Three electronic databases were searched to identify relevant studies. The methodological quality and mean differences of the change in clinical attachment level and probing depth were analyzed according to Cochrane review methods. Results: Twelve studies were included in the methodological assessment and nine studies were suitable for inclusion in the meta-analysis. The mean difference in the clinical attachment level gain did not differ significantly between the nonsteroidal anti-inflammatory drugs and control groups at any observation time. The highest mean difference in clinical attachment level gain was 0.30 mm at 4 weeks (95% confidence interval = -0.37 to 0.97). There was a significant mean difference in the probing depth reduction, of 0.34 mm (95% confidence interval = 0.29 to 0.40) at 6 weeks. Conclusion: Therefore, nonsteroidal anti-inflammatory drugs have additional therapeutic effect when administrated with nonsurgical periodontal treatment. (J Dent Rehabil Appl Sci 2017;33(1):7-18)
Introduction
Periodontitis is an infectious disease initiated by periodontal pathogens. 1 It is well known that periodontal disease primarily develops due to bacterial infection. However, the initiation and progression of the diseases can vary among individuals based on genetic traits, systemic conditions, and environmental factors. [2] [3] [4] There is a large body of literature showing that both surgical and nonsurgical peri-odontal therapies are effective against periodontitis by removing pathogenic dental plaque and calculus. 5 However, some patients do not respond to conventional periodontal therapy 6 or show highly elevated susceptibility to periodontal infection. 7 Investigations of the mechanism underlying these phenomena have revealed that the immune response of subjects appears to play a critical role in the development and manifestation of periodontal diseases. 8, 9 In order to provide a better treatment modality to patients who are highly susceptible to periodontal diseases, host modulation using various therapeutic agents targeting the manipulation of the inflammatory pathway has been proposed as an adjunctive treatment with conventional periodontal therapy. [10] [11] [12] [13] Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most potent agents due to their direct inhibition of cyclooxygenase, which is responsible for the production of arachidonic acid metabolites. These metabolites are involved in tissue breakdown in periodontal diseases 14 via the activation of the secretion of matrix metalloproteinase and osteoclasts. NSAIDs are therefore expected to have a strong efficacy for host modulation in patients with periodontal diseases.
In spite of the effectiveness of NSAIDs in host modulation, few systematic literature reviews have attempted to fully evaluate their impact in periodontal therapies, although it has been well established that the therapeutic effect of a host modulation agent can be synergistic when it is coupled to a cause-related periodontal therapy. [15] [16] [17] Therefore, the aim of this review was to compare the effects of adjunctive use of NSAIDs with nonsurgical periodontal treatment (NSPT) on periodontal disease based on the available literature. Following focused question was addressed: "In patients with periodontal disease, is there an additional benefit of the oral administration of NSAIDs adjunctive with NSPT compared to control in terms of the clinical attachment level (CAL), probing depth (PD), and adverse outcomes in randomized controlled trials?"
Materials and Methods

Data and literature source
Relevant studies in electronic databases were identified by searching MEDLINE (from January 1, 1976 to March 11, 2015) , EMBASE (from January 1, 1985 to March 11, 2015) , and the Cochrane Central Register of Controlled Trials (from January 1, 1987 to March 11, 2015) without any restriction on language according to the Cochrane review methods. 18 A search strategy was developed by combining text words and MeSH terms for MEDLINE and adapted to other databases (supplementary Appendix 1). In addition, key articles on periodontology published in the Journal of Periodontology, Journal of Clinical Periodontology, or Journal of Periodontal Research as well as the gray literature from January 1, 2005 to March 11, 2015 were searched manually for any missed relevant articles. 19 
Inclusion criteria and study selection
To be eligible for inclusion in our review, the studies had to fulfill the following criteria:
1. Randomized controlled trials that compared the effects of NSAIDs and NSPT versus NSPT only. 2. Subjects diagnosed with one of the classified types of periodontal disease, 20 with the exception of gingival diseases and periodontitis associated with endodontic lesions. 3. All drugs administered via the oral route. 4. NSPT performed in both the NSAIDs and control groups. 5. Outcome included at least one clinical parameter of CAL or PD.
Data extraction and analysis
Studies to be included were selected independently by two reviewers (D.Y.K. and J.C.P.). After removing duplicates, suitable studies were identified by applying screening at the title/abstract level and then by reading the full texts. The level of agreement between reviewers in the screening process was assessed using Cohen's kappa coefficient. 21 Data of identified studies were extracted independently by two reviewers using a prefabricated data extraction form. Disagreement was discussed by two reviewers, and if not resolved it was mediated by taking advice from the other authors. The methodological quality of each included study was assessed independently using the Cochrane risk-of-bias assessment tool. 22 Suggested protocols were searched as part of the evaluation of reporting bias. 23 To describe characteristics of the studies, data about subject populations and experimental designs were collected. The mean and standard deviation (SD) values of the changes in CAL and PD were collected for each group at baseline and the time of observation. If there were ambiguous or incomplete data, we contacted the authors by e-mail. The differences in the CAL gain and PD reduction between groups were calculated as mean and 95% confidence interval values. The results of the quantitative analysis were checked using both random-effect and fixed-effect models. To quantify heterogeneity, the I 2 statistic was used to estimate the proportion of inconsistency from true differences. 24 Review Manager software (v.5.2, Nordic Cochrane Center, Copenhagen, Denmark) was used to perform the statistical tests.
Results
Identification of studies
The search of the databases initially identified 712 articles ( Fig. 1 ), of which 287 duplicated articles were removed. At title/abstract screening, 400 articles that clearly were not consistent with the inclusion criteria were excluded. Reading the full texts of the remaining 25 articles resulted in the identification of 12 potentially relevant studies. The reasons for excluding 13 articles are tabulated in supplementary Appendix 2. The agreement between the two reviewers throughout the screening process was rated as good, with a Cohen's kappa coefficient of 0.69.
Study characteristics and patient populations
The demographic and experimental characteristics of the included studies are summarized in Table 1 . There were differences between the studies in the kind of NSAIDs, daily dose, administration period, and observation period. The examined area, type of tooth, and number of data points per subject also varied among the studies. Treatment outcomes were presented using various outcome variables. For most of the studies, CAL or PD was reported as mean ± SD values at the subject-level observation unit. [25] [26] [27] [28] [29] [30] [31] [32] [33] 
Methodological quality of included studies
The included studies were assessed using the Cochrane risk-of-bias assessment tool (Fig. 2 , supplementary Appendix 3). Publication bias could not be assessed due to the small number of appropriate studies (7 for CAL and 8 for PD), since asymmetry of the funnel plot is generally only tested when at least 10 studies are included in a meta-analysis.
Effects of interventions
Data reported as mean ± SD values with the subject-level observation unit pooled by observation time. The differences in the CAL gain and PD reduction between NSAIDs and control groups using a random-effect model are illustrated in Fig. 3 and Fig.  4 as mean and 95% confidence interval values. There was no significant difference in the mean CAL gain at any observation time (Fig. 3) . A significant reduction in PD-with a mean difference of 0.34 mm (95% confidence interval = 0.29 to 0.40)-was seen only at 6 weeks relative to the control group (Fig. 4) .
The number of adverse reactions, the reasons for dropouts, and reports of adverse reactions are listed in Table 1 . Reddy et al. 31 reported that their dropouts were due to gastrointestinal discomfort in the group receiving meclofenamate at 200 mg/day, but the reason for other dropouts was unknown in most cases (e.g., lost to follow-up or a discontinued study). 
Discussion
The studies included in this meta-analysis exhibited a substantial heterogeneity, which was due to a few reports of significantly higher mean differences in CAL gain or PD reduction in the NSAIDs group than the control group. For instance, Ng and Bissada 29 reported a higher mean difference in the NSAIDs group at 6 weeks posttreatment, but this was due to a smaller CAL loss in the NSAIDs group compared to the control group, rather than to a superior CAL gain. Likewise, Buduneli et al. 27 enrolled patients with a deeper PD at baseline in the NSAIDs group than the control group, and this may have resulted in a superior PD reduction considering that scaling and root planing reportedly produces a greater PD reduction in sites with a deeper PD. 5, 34 The following differences accounted for the heterogeneity. Firstly, subjects were recruited in each study using different inclusion criteria and exclusion criteria. Secondly, additional oral prophylaxis or oral hygiene instruction was either not planned or, if it was planned, the schedule varied among the studies. These additional procedures may produce an appropriately maintained plaque state in the enrolled patients, and they may have resulted in the treatment responses differing among the studies. In addition, the state of plaque deposition was not presented as a unified outcome variable. Moreover, kinds of NSAIDs the daily dose, administration period, and observation period of the regime varied among the studies. These differences may have contributed to the inconsistent results.
It is well known that NSAIDs may induce gastrointestinal irritation, and two of the patients who dropped out for this reason had received meclofenamate at 200 mg/day for 6 months. 31 To minimize gastrointestinal irritation and ulcers from NSAIDs, limiting the dose or co-administration with protonpump inhibitors or H 2 -receptor antagonist can be considered. 35 It has been reported that NSAIDs can impair oral mucosal repair as well as gastrointestinal mucosa, 36 so whether NSAIDs compromise gingival repair following NSPT also needs to be investigated.
A recent nationwide retrospective study failed to show any benefit of low-dose aspirin when comparing mean CAL and PD data from 2 335 subjects in a national health and nutrition examination survey. 37 In addition, systematic reviews have found no clear effect of NSAIDs on clinical outcomes. 17 Our present results are in accordance with these previous findings. However, two reviews have found positive effects of NSAIDs on gingival inflammation and periodontal-disease progression by reducing the rate of alveolar bone resorption. 38, 39 These conflicting findings are probably due to the bone preservation effect of NSAIDs and it might not be reflected in clinical parameters including PD or CAL. Also, it would take a long time for bony changes to be measurable by periodontal probes.
The methodological quality of the included studies was not high due to the lack of information. In addition, there were problems associated with partial tooth recording (i.e., including only specific types of teeth), which has the risk of overestimating or underestimating the periodontal condition of patients. 40 Not only an adequate number of subjects but also an adequate number of data points from different types of teeth are needed to accurately reflect the status of included subjects. Taking these factors into account, further randomized controlled trials are needed to achieve a high methodological quality, involving subject-level observation units and sufficient data points via full-mouth observations as well as the inclusion of sufficient subjects to achieve an adequate statistical power for detecting a clinically meaningful effect size of NSAIDs.
Conclusion
The present review found clinical benefit for NSAIDs and NSPT over NSPT alone in some administration periods. It is difficult to conclude definitively whether a specific regime is superior to others, although some studies have found significant benefits and the others do not, due to the smallness of the included samples and the substantial heterogeneity among studies.
